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Hutchinson–Gilford progeria syndrome (HGPS) is caused by point mutations that increase utilization of an
alternate splice donor site in exon 11 of LMNA (the gene encoding lamin C and prelamin A). The alternate spli-
cing reduces transcripts for wild-type prelamin A and increases transcripts for a truncated prelamin A (pro-
gerin). Here, we show that antisense oligonucleotides (ASOs) against exon 11 sequences downstream from
the exon 11 splice donor site promote alternate splicing in both wild-type and HGPS fibroblasts, increasing
the synthesis of progerin. Indeed, wild-type fibroblasts transfected with these ASOs exhibit progerin levels
similar to (or greater than) those in fibroblasts from HGPS patients. This progerin was farnesylated, as
judged by metabolic labeling studies. The synthesis of progerin in wild-type fibroblasts was accompanied
by the same nuclear shape and gene-expression perturbations observed in HGPS fibroblasts. An ASO corre-
sponding to the 50 portion of intron 11 also promoted alternate splicing. In contrast, an ASO against exon 11
sequences 50 to the alternate splice site reduced alternate splicing in HGPS cells and modestly lowered pro-
gerin levels. Thus, different ASOs can be used to increase or decrease ‘HGPS splicing’. ASOs represent a
new and powerful tool for recreating HGPS pathophysiology in wild-type cells.
INTRODUCTION
Hutchinson–Gilford progeria syndrome (HGPS), a rare pedi-
atric progeroid syndrome, is caused by single-nucleotide sub-
stitutions in exon 11 of LMNA. These point mutations promote
usage of an alternate splice donor site located within exon 11
(1–3). The alternate splicing simultaneously reduces wild-
type prelamin A transcripts and increases the production of a
mutant prelamin A transcript lacking the last 150 nucleotides
of exon 11. This mutant transcript encodes a mutant prelamin
A protein, commonly called progerin, containing an internal
deletion of 50 amino acids. Progerin retains a C-terminal
CaaX motif (encoded by exon 12) that triggers protein
prenylation (4–7). The production of progerin interferes
with the integrity of the nuclear lamina, causing misshapen
nuclei, and also adversely affects other important cellular pro-
cesses, such as mitosis and cell proliferation (4–7). A gene-
targeted HGPS mouse model has clearly established that the
hallmark phenotypes of progeria are caused by the production
of progerin (8,9).
The most common point mutations causing HGPS optimize
a cryptic splice donor site in exon 11 (10). This splice donor
site, CAG#GTGGGC, is used at trace levels in wild-type
cells (10). However, the levels of alternatively spliced tran-
scripts in wild-type cells are so low that they are generally
undetectable on ethidium bromide-stained agarose gels of
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RT–PCR products (3) [although one group did report finding
trace amounts of progerin transcripts when large amounts of
the RT–PCR product was loaded (10)]. In any case, the
levels of alternatively spliced transcripts are so low that pro-
gerin in wild-type cells is not normally detected by western
blotting, even on heavily loaded gels (11,12). The most
common point mutation causing HGPS [G608G(GGC.
GGT)] increases usage of the alternate splice site so that
40% of all prelamin A transcripts are alternatively spliced
(12). Rare point mutations associated with very high levels
of alternate splicing and very high levels of progerin pro-
duction lead to particularly severe forms of progeria (12).
Many studies investigating the effects of progerin have used
fibroblasts from HGPS patients (2,3,11,13–15). These exper-
iments have been informative, but their interpretation can be
difficult because of prominent phenotypic differences
between different HGPS fibroblast cell lines—presumably
differences related to passage number and the age, sex and
genetic background of the donor patient. Other studies have
relied on expressing progerin in cell lines that already express
a full complement of wild-type lamin proteins (6,7,13,14,16).
Although these studies have also been useful, for example in
defining the impact of progerin on nuclear shape and cell
growth (6,7,16), they also have distinct limitations, given that
overexpression of even wild-type lamins can cause abnormal-
ities in nuclear shape and gene expression (17).
Because of the problems associated with progerin over-
expression and the phenotypic variability of human HGPS
fibroblasts, we reasoned that it would be useful to develop
techniques to increase ‘HGPS alternate splicing’ and progerin
production in wild-type cells. If it was possible to vastly
increase the alternate splicing in wild-type cells, it would
provide an important new approach for assessing the impact
of progerin in cells—and one that would faithfully mirror the
molecular pathophysiology of HGPS (i.e. increased progerin
expression with reduced expression of wild-type prelamin A).
Several recent studies have shown that antisense oligonu-
cleotides (ASOs) have the potential to modulate splice site util-
ization (18–21). For example, an ASO directed against exon 7
of SMN2 promotes the inclusion of exon 7 in the mature tran-
script, whereas other ASOs promote skipping of that same
exon (18). In the current study, we examined multiple ASOs
on the utilization of the splice donor site in exon 11 of LMNA.
We identified multiple ASOs that increased levels of progerin
transcripts. Remarkably, these ASOs converted wild-type fibro-
blasts into cells that synthesize high levels of progerin and
manifest cellular and molecular hallmarks of HGPS fibroblasts.
In addition, one of the ASOs, located upstream from the splice
donor site, reduced alternate splicing and modestly lowered
levels of progerin in HGPS fibroblasts.
RESULTS
To determine if ASOs could affect the utilization of the splice
donor site in exon 11 of LMNA, we transfected fibroblasts with
ASOs directed against exon 11 sequences. All of the ASOs
contained a 20-O-methoxy-ethyl (20-MOE) ribose modification
and a phosphodiester backbone. Testing of more than 25
ASOs, located within 50 bp of the alternative splice site,
identified multiple ASOs that modulated utilization of the
splice donor site, as judged by RT–PCR (Supplementary
Material, Figs S1 and S2). Nine ASOs, all located 47 bp
downstream from the alternative splice site (c.1849–1882) pro-
moted alternative splicing in HGPS fibroblasts (e.g. ASO 324),
resulting in more progerin transcripts and fewer wild-type pre-
lamin A transcripts (Supplementary Material, Figs S1B and
S2B, Fig. 1B). In contrast, only one ASO (ASO 365), located
51 bp upstream from the splice donor site, consistently
reduced progerin transcripts (Fig. 1B). The ratio of progerin
to prelamin A transcripts, as judged by image analysis,
increased from 1.4 to 3.9 in HGPS cells transfected with ASO
324, relative to cells transfected with a scrambled ASO, ASO
333. In contrast, the ratio decreased from 1.4 to 0.92 in HGPS
cells transfected with ASO 365. Interestingly, ASOs directed
against the exon 11 splice donor site (e.g. ASOs 076 and 790)
had minimal, if any, effects on splicing. To measure the
changes in splicing more precisely, we assessed transcript
levels by quantitative RT–PCR in two HGPS cell lines
(AG03513 and GM01972). These studies revealed that ASO
324 increased progerin transcripts 2.6-fold relative to the
control ASO, whereas ASO 365 lowered progerin levels
1.8-fold (relative to the control ASO) (Fig. 1C).
These studies involving HGPS fibroblasts showed that
ASOs can change progerin transcript levels, but the mechan-
ism was not entirely clear. One possibility, of course, is that
the ASOs affected splice site utilization, but alternatively,
the results could be explained by an effect of the ASO
on the relative stability of the two transcripts. We reasoned
that if the ASOs changed progerin transcript levels by altering
splicing, then the ASOs might induce high levels of progerin
transcripts in wild-type cells, where progerin transcripts are
normally present in trace amounts (undetectable on ethidium
bromide-stained agarose gels of RT–PCR products, as
shown in Supplementary Material, Figs S1B and S2B). To
explore this idea, wild-type fibroblasts were transfected with
ASO 324 and progerin transcript levels were evaluated by
RT–PCR. Remarkably, the predominant RT–PCR product
in ASO 324-transfected wild-type cells was shorter and had
the same mobility as the progerin product obtained with
HGPS fibroblasts; in addition, the levels of wild-type prelamin
A transcripts were decreased (Fig. 1D and Supplementary
Material, Fig. S2). Wild-type cells that had been transfected
with the control ASO (ASO 333) expressed only the full-
length prelamin A transcript.
Both of the RT–PCR products from ASO 324-transfected
wild-type cells were cloned and sequenced; the longer
RT–PCR product was derived from the full-length prelamin
A transcript, whereas the shorter product was derived from
the alternatively splice progerin transcript (Fig. 1D).
We identified multiple ASOs that promoted the production
of progerin transcripts in HGPS fibroblasts (Supplementary
Material, Fig. S2). Of these, ASOs 074 and 324 (located 43
and 47 bp downstream from the HGPS splice-donor site,
respectively) were the most potent. Each ASO that stimulated
synthesis of progerin transcripts in HGPS fibroblasts had
similar effects in wild-type fibroblasts (Supplementary
Material, Fig. S2).
We were concerned that ASOs that promoted alternate spli-
cing, such as ASOs 074 and 324, might bind to and promote
Human Molecular Genetics, 2009, Vol. 18, No. 13 2463
the degradation of progerin transcripts, thereby preventing the
synthesis of progerin protein. However, this was not the case,
as large amounts of progerin protein were observed in ASO-
transfected wild-type cells (Fig. 2A). Transfection of ASO
074 into either wild-type or HGPS fibroblasts resulted in a
concentration- and time-dependent increase in the amount of
progerin, as judged by western blotting with a lamin A/C anti-
body (Fig. 2A and B). Progerin persisted for at least 5 days
after transfection, and the amounts of progerin in wild-type
cells were similar to, or even greater, than the amount in non-
transfected HGPS fibroblasts (Fig. 2A and B). RT–PCR
studies on ASO 074-transfected cells showed that wild-type
prelamin A transcripts fell at the same time that progerin tran-
scripts increased. Consistent with these RT–PCR results,
quantitative image analyses of western blots revealed that
mature lamin A levels (relative to lamin C) in ASO
074-transfected cells decreased by 68.3+ 8.5%, compared
with cells transfected with the control ASO (average of
results with three different wild-type fibroblast cell lines). In
contrast, transfection of ASO 365 into HGPS fibroblasts
reduced progerin levels in cells (Fig. 2C), a result that was pre-
dictable from the RT–PCR studies (Fig. 1B).
Most studies on progerin have relied on fibroblast cell lines
harvested from patients with HGPS. However, the ASO-based
approach provides the opportunity to studying progerin in cell
lines derived from other tissues. For example, transfection of
HeLa cells with ASO 074 resulted in the production of signifi-
cant amounts of progerin (Fig. 2D). This technique also makes
it possible to induce progerin expression in fibroblasts with
other defects in prelamin A processing. Fibroblasts from
restrictive dermopathy (RD) patients normally accumulate
farnesyl-prelamin A as a result of a deficiency in ZMPSTE24
Figure 1. Modulating the utilization of the exon 11 splice donor site with antisense oligonucleotides corresponding to sequences within exon 11 of human
LMNA. All of the antisense oligonucleotides (ASOs) contained a 20-O-methoxy-ethyl ribose backbone. (A) Exons 11 and 12 of LMNA, depicting both ‘wild-type
splicing’ and ‘HGPS splicing’ (which uses the alternate splice donor site in exon 11). Also shown are the locations of ASOs located upstream of the alternate
splice donor site (i.e. 365), ASOs downstream from the splice donor site (i.e. 324) and ASOs that straddle the site (i.e. 076 and 790). (B) SYTO 60-stained
agarose gel showing RT–PCR products of RNA prepared from an HGPS cell line. The PCR products correspond to wild-type prelamin A and progerin tran-
scripts. Transfection with ASO 324 increases progerin transcripts, whereas ASO 365 lowers progerin transcripts, as judged by image analysis on a LI-COR
infrared scanner. (C) Quantification of progerin transcripts, by quantitative RT–PCR, in HGPS fibroblasts (AG03513 and GM01972) transfected with different
ASOs. Results are plotted relative to progerin transcript levels in fibroblasts transfected with ASO 333. (D) SYTO 60-stained gel showing relative levels of
wild-type prelamin A and progerin transcripts in wild-type fibroblasts, HGPS fibroblasts and wild-type fibroblasts transfected with either ASO 324 or control
ASO 333. Also shown are DNA sequencing chromatograms of RT–PCR products corresponding to wild-type prelamin A transcripts in ASO 324-treated wild-
type cells (upper), progerin transcripts in ASO 324-treated wild-type cells (middle) and progerin transcripts in HGPS fibroblasts (lower).
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(the prelamin A protease) (22). However, when RD fibroblasts
were transfected with ASO 324, they also produced progerin
(Fig. 2D).
In a recent study, Moulson et al. (12) showed that a particu-
larly severe form of progeria was caused by a LMNA point
mutation involving the first nucleotide of intron 11
(c.1968 þ 1G . A). That mutation promoted utilization of
the alternate splice donor site in exon 11, resulting in large
amounts of progerin synthesis. We therefore speculated that
ASOs directed against the beginning of intron 11 might also
promote alternate splicing and progerin synthesis. Indeed,
when human fibroblasts were transfected with an ASO
directed against the first 20 nucleotides of intron 11 (ASO
893), the fibroblasts produced progerin (Fig. 3A and B).
ASOs directed against sequences immediately upstream or
downstream from the intron 11 splice donor site (ASOs 890,
891, 892 and 894) had no effect (Fig. 3A and B).
Progerin is predicted to be farnesylated, and this modifi-
cation has been proposed to be important in the pathogenesis
of disease (23,24). To determine if the progerin produced by
ASO-transfected cells is farnesylated, ASO 074-transfected
fibroblasts were metabolically labeled with 8-anilinogeraniol
(AG) in the presence or absence of a farnesyltransferase
inhibitor (FTI). AG is incorporated into anilinogeranyl dipho-
sphate (AGPP) within cells and used as a substrate for protein
farnesyltransferase (FTase). The incorporation of the AGPP
into proteins can be monitored by western blotting with a
monoclonal antibody against AG. This approach was recently
used to show that a GFP-tagged progerin fusion protein was
farnesylated in HeLa cells (7). We used AG metabolic labeling
to examine progerin farnesylation in HGPS fibroblasts. These
studies showed that the progerin in HGPS fibroblasts is farne-
sylated and that this farnesylation could be blocked with an
FTI (Fig. 4A). Interestingly, the AG experimental approach
is quite sensitive; we detected farnesylation of the full-length
prelamin A, even though only small amounts of farnesyl-
prelamin A are present in cells (Fig. 4A). AG labeling
studies also revealed that the progerin in ASO 074-transfected
fibroblasts was farnesylated (Fig. 4B). When the ASO
074-transfected fibroblasts were treated with an FTI, the farne-
sylation of progerin was eliminated (Fig. 4B).
We predicted that the increased production of progerin in
ASO 074-transfected wild-type and HGPS fibroblasts would
be associated with a higher frequency of misshapen cell
nuclei. Indeed, in two independent experiments, the frequency
of cells with misshapen nuclei was higher in ASO
Figure 2. Western blots with an antibody against lamin A/C showing that transfection of antisense oligonucleotide 074 yields higher levels of progerin
expression. (A) Western blot of wild-type fibroblasts (GM01651) and HGPS fibroblasts (AG11513) 2 days after transfection with ASO 074, revealing progerin
in the wild-type fibroblasts and increased levels of progerin in the HGPS fibroblasts. (B) Western blot of a wild-type fibroblast cell line (GM01651) 1–5 days
after transfection with ASO 074, revealing a time-dependent increase in progerin expression (similar results were observed with cell line AG07095; data not
shown). In both experiments, the levels of progerin in wild-type fibroblasts exceeded those in HGPS fibroblasts. (C) Western blot showing that transfection
of ASO 365 into HGPS fibroblasts (AG11513) results in slightly reduced levels of progerin. (D) Western blot of ASO 074-transfected restrictive dermopathy
(RD) fibroblasts and HeLa cells. Progerin was found in cell extracts prepared 2 days after the transfection.
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074-transfected cells (P, 0.0001, x2-test) (Fig. 5A and B).
We found a somewhat lower level of misshapen nuclei in
ASO 074-transfected fibroblasts than in HGPS fibroblasts,
but this was not unexpected. The HGPS fibroblasts used in
these experiments were late-passage cells, which are known
to exhibit more severe nuclear shape abnormalities (16).
To study consequences of progerin expression in cells, we
examined gene and protein expression patterns in ASO-
transfected wild-type fibroblasts. Previous studies had
suggested that the expression of five genes (i.e. HAS3,
CCL8, MMP14, MMP3 and TIMP3) was perturbed in HGPS
fibroblasts when STAT3 was unchanged (4). In cells that had
been transfected with ASO 324, we found that, in addition
to progerin, the expression of HAS3 and CCL8 was signifi-
cantly increased (P ¼ 0.030 and 0.005, respectively, in three
independent cell lines); however, there were no consistent
changes in the other three genes (Supplementary Material,
Fig. S3). In follow-up experiments, we were unable to
confirm consistent perturbations of the other three genes (i.e.
MMP14, MMP3 and TIMP3) in six different HGPS fibroblast
cell lines (data not shown). More recently, increased
expression of Notch signaling pathway effectors was observed
in fibroblasts expressing an inducible GFP–progerin fusion
protein (25). Consistent with those findings, HES1 was
increased by 1.6-fold (P ¼ 0.003) and HEY1 was increased
by 2.0-fold (P ¼ 0.044) in wild-type fibroblasts 3 days after
transfection with ASO 074 (relative to levels in wild-type
fibroblasts transfected with ASO 333).
The proteome of fibroblasts expressing progerin was ana-
lyzed by two-dimensional difference gel electrophoresis
(2D-DIGE). Fibroblasts were transfected with ASO 324 or
ASO 333 (the control ASO), and after 3 days, proteins from
cell extracts were prepared and labeled with cyanine dyes.
The extracts were mixed together, separated by 2D-gel elec-
trophoresis, and differences in expression were identified by
fluorescence image analysis (after normalization to the internal
standard). In two independent experiments, 24 proteins with
perturbed expression patterns were identified (P , 0.05,
ANOVA) (Fig. 6); 15 proteins had decreased expression and
9 were increased. Proteins with a change in expression more
than 1.5-fold were submitted for mass spectrometry, and 12
of the 15 that were submitted were identified (Supplementary
Material, Table S3). It was reassuring that one of the proteins
with increased expression in the ASO 324-transfected cells
was progerin, and one of the proteins with reduced expression
was lamin A. Several mitochondria-associated proteins
were increased in the progerin-expressing cells, including
Figure 3. Western blot with an antibody against lamin A/C showing that trans-
fection of an antisense oligonucleotide directed against the splice donor
sequence at the beginning of intron 11 results in progerin expression. (A)
Schematic showing the location of five ASOs near the splice donor sequence
at the beginning of intron 11. (B) Western blot of extracts from wild-type
fibroblasts (AG07095) showing that transfection of ASO 893 (corresponding
to the first 20 nucleotides of intron 11) results in the production of progerin.
Figure 4. Metabolic labeling experiments showing that the progerin that
accumulates in antisense oligonucleotide-transfected wild-type fibroblasts is
farnesylated. Fibroblasts were metabolically labeled with 8-anilinogeraniol
(AG) in the presence or absence of a protein farnesyltransferase inhibitor
(FTI) (ABT-100). After entering cells, AG is incorporated into anilinogeranyl
diphosphate (AGPP), which is used as a substrate by protein farnesyltransfer-
ase. The incorporation of the AGPP into proteins can be monitored by western
blotting with an antibody against AG. (A) Western blot of HGPS fibroblast
extracts, performed with an Odyssey infrared imaging system, showing that
progerin is farnesylated. Shown is the merged image of western blots with
an antibody specific for lamin A/C (red) and an antibody against AG
(green) before (left panel) and after (right panel) immune precipitation with
a lamin A/C antibody. Incorporation of AG into progerin was blocked by
the FTI. (B) Western blot of ASO-transfected wild-type fibroblasts showing
that the progerin is farnesylated. Wild-type fibroblasts were transfected with
ASO 074 to induce progerin synthesis and incubated with the AG substrate.
After 2 days, extracts were prepared and the A-type lamins isolated by
immune precipitation with an antibody against lamin A/C. The progerin in
the wild-type cells was farnesylated (green), and this farnesylation could be
blocked with an FTI.
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Mn-superoxide dismutase (Mn-SOD), Mn-SOD precursor,
voltage-dependent anion channel 2 and phosphoenolpyruvate
carboxykinase 2 (Supplementary Material, Table S3).
DISCUSSION
The discovery of mutations causing HGPS (1–3) was quite
important, as it provided an entry point for investigating the
molecular mechanisms underlying progeria. During the past
few years, the investigation of HGPS pathogenesis has relied
heavily on studies involving either HGPS fibroblasts or
tumor cell lines overexpressing progerin (26). Although
these approaches have been useful, they have clear limitations.
Different HGPS fibroblast cell lines from cell repositories are
phenotypically different (16), and entirely appropriate control
cell lines are rarely available. With the overexpression
approach, it is often difficult to match expression levels for
progerin and control lamin constructs, and it is sobering that
wild-type lamins as well as commonly used N-terminal
protein tags can alter nuclear morphology (17) and gene
expression (25). In the current study, we describe an entirely
new approach for expressing progerin in wild-type cells—by
inducing ‘HGPS alternative splicing’ within exon 11 of
LMNA. We demonstrate that ASOs directed against sequences
downstream from the alternate splice donor site promote
‘HGPS splicing’ in wild-type cells, leading to significant pro-
gerin levels in cells and morphological and gene-expression
hallmarks of HGPS. This ASO approach faithfully reproduces
the proximal event in the pathogenesis of HGPS—increased
alternate splicing at the expense of reduced levels of normal
splicing. We found no evidence that two of the most potent
ASOs in promoting alternate splicing (ASOs 074 and 324)
did not lower the overall expression of lamin proteins. This
is not particularly surprising, as the 20-MOE ribose oligonu-
cleotides that we used do not support elimination of LMNA
transcripts by a short interference RNA activity (27).
These studies provide a robust and reproducible approach
for defining the impact of progerin on cells. The amount of
progerin in the ASO-transfected wild-type fibroblasts
exceeded those in HGPS fibroblasts, and the progerin in ASO-
transfected cells was farnesylated (like the progerin in HGPS
fibroblasts). When the ASOs were transfected into HGPS
fibroblasts, the levels of progerin increased markedly. The
ASO method for expressing progerin is versatile, in that it is
possible to achieve different levels of progerin synthesis
simply by titrating ASO concentrations.
Alternative splicing within exon 11 was promoted most
effectively by ASOs directed against sequences centered
47 bp downstream from the alternate splice donor site (e.g.
ASOs 324 and 074). ASOs centered . 9 bp upstream or
downstream from ASO 324 were less effective. What is the
mechanism by which ASOs 324 and 074 promote the alternate
spice site utilization? We suspect that these ASOs likely inter-
fere with exonic splicing enhancers (ESEs). Proper mRNA
splicing clearly depends on intronic cis-elements—the 50
splice site, the 30 splice site and the branch site (28).
However, proper splicing also depends on ESEs, which are
specific sequences within exons that promote proper exon defi-
nition. ESEs are thought to serve as binding sites for specific
serine/arginine-rich (SR) proteins; the SR proteins bind to
specific RNA sequences and promote proper exon identifi-
cation by the splicing machinery (28). Of note, a strong
SRp40 binding site (TCACTCG) is located within the exon
11 sequences that are targeted by ASO 074 and 324 (http://
rulai.cshl.edu/tools/ESE2/index.html). Thus, it seems likely
that ASOs 074 and 324 mask an ESE required for exon
definition, reducing normal splicing and increasing abnormal
splicing.
Although our studies showed that specific ASOs directed
against exon 11 sequences promoted alternate splicing, it
Figure 5. Increased percentage of misshapen nuclei in wild-type and HGPS
fibroblasts after transfection with antisense oligonucleotide 074. (A) Epifluor-
escence microscopy showing increased numbers of misshapen nuclei in wild-
type fibroblasts transfected with ASO 074, which promotes alternate splicing
and progerin synthesis. ASO 333, which has no effect on splicing, was used as
a control. (B) Bar graph comparing the frequency of misshapen nuclei in wild-
type and HGPS fibroblasts transfected with ASOs 074 and 333. The ratios
inside the bars reflect the number of misshapen nuclei divided by the total
number of nuclei that were scored. The solid black circles show the percentage
of misshapen nuclei in two independent experiments. Differences in the fre-
quency of misshapen nuclei were assessed with a x2-test.
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would be a mistake to conclude that exon 11 sequences were
the only sequences that affect splicing. Indeed, an ASO corre-
sponding to sequences at the beginning of intron 11 also
induced significant amounts of progerin expression. The
latter findings were in keeping with genetic observations by
Moulson et al. (12), who showed that a single-nucleotide
mutation at the beginning of intron 11 dramatically increased
levels of progerin transcripts.
We identified one ASO (ASO 365), located upstream from
the alternate splice donor site, that suppressed alternative spli-
cing, lowered levels of progerin transcripts and lowered pro-
gerin levels in cells. However, the magnitude of the effects
was fairly modest and certainly was less impressive, at both
the RNA and protein levels, than the effects of ASO 324 or
ASO 074 in promoting progerin synthesis. An earlier study
found that repeated transfections of a morpholino oligonucleo-
tide directed against the exon 11 splice donor site inhibited
alternate splicing (4). In the current study, we tested multiple
ASOs with sequences spanning the exon 11 splice donor site,
and the effects of these oligonucleotides were small, and
clearly were less impressive than the modest effects of ASO
365. We do not why our results were different from the
earlier study (4), but several factors could be relevant. The
ASOs in our studies were 20-MOE ribose oligonucleotides
rather than morpholino oligonucleotides. Also, the concen-
trations of ASOs that we used (2.5–100 nM) were lower than
those used in the earlier study (15–40 mM).
Although the reduction in progerin synthesis with ASO 365
was modest, it is conceivable that this ASO, or other ASOs
with similar properties, could be therapeutically useful. Pro-
gerin transcript and protein levels were reduced by only
30% with ASO 365, but even this small effect might still
be relevant from a therapeutic perspective. Relatively small
changes in progerin production have been shown to have a
major impact on the severity of progeria (12). Also, reducing
the levels of farnesyl-prelamin A in Zmpste24-deficient mice
by 50% completely eliminated disease phenotypes (23).
Another reason for optimism about the possibility of ASO
therapy is that 20-MOE ribose oligonucleotides are extremely
stable and have already been tested extensively in humans
(29–31).
Our ability to modulate alternative splicing within exon 11
ASOs raises an extremely intriguing possibility for future
studies—that it might be possible to use ASOs to modulate
the physiologically normal alternative splicing event that
occurs within exon 10. Alternative splicing within exon 10
controls the relative rates of synthesis of lamin C and prelamin
A transcripts. Recent studies by our group (32) showed that
mice lacking prelamin A (‘lamin C-only’ mice) are healthy,
fertile and robust, strongly suggesting that prelamin A and
lamin A are dispensable, at least in the laboratory mouse.
Identifying an ASO that promotes the production of lamin C
transcripts at the expense of prelamin A transcripts might
pave the way to an entirely new therapeutic approach for
HGPS (32).
MATERIALS AND METHODS
Fibroblast cell lines
Human HGPS fibroblasts (AG11498, AG06917, AG11513,
AG03513, AG06297 and GM01972; all with the G608G
Figure 6. Two-dimensional gel electrophoresis experiments revealing distinct patterns of protein expression in wild-type human fibroblasts after transfection
with ASO 324, an antisense oligonucleotide that promotes alternate splicing and progerin synthesis, or ASO 333, a control oligonucleotide that has no effect
on splicing. Wild-type fibroblasts (CRL-1474) were transfected with ASO 324 or ASO 333, and soluble extracts were labeled with cyanine dyes (red and
green). Equal amounts of the extracts were mixed together and fractionated by 2D-gel electrophoresis. The gel was imaged on a Typhoon TRIO scanner
and individual protein spots were quantified with DeCyder. In the merged image (far right), red spots represent proteins that increase in ASO 324-transfected
cells, whereas green spots represent proteins that decrease (relative to cells transfected with ASO 333). Two independent experiments are shown. The locations of
eight proteins (identified by mass spectrometry) are shown in one of the experiments.
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mutation), control human fibroblasts (CRL-1474, AG07095,
AG08470, AG16409, CRL-7469 and GM01651) and HeLa
cells were from the American Type Culture Collection
(Manassas, VA, USA) or Coriell Cell Repository (http://
locus.umdnj.edu/ccr/) (3). Skin fibroblasts from a RD patient
(22) were provided by Drs Casey Moulson and Jeffrey
Miner (Washington University, St Louis, MO, USA). Cells
were cultured with conditions recommended by the cell repo-
sitories. In some experiments, fibroblasts were incubated with
an FTase inhibitor, ABT-100 (33). Untreated fibroblasts were
incubated with the vehicle alone (dimethylsulfoxide).
ASOs and cell transfection experiments
Uniform 20-MOE ASOs with a phosphorothioate backbone
were synthesized with an Applied Biosystems 380B auto-
mated DNA synthesizer (Applied Biosystems, Foster City,
CA, USA) as described previously (29). ASOs used in this
study are listed in Supplementary Material, Table S1.
The ASOs were transfected into fibroblasts as described
(32,34). Fibroblasts were plated in 6- or 24-well dishes and
allowed to adhere overnight. The fibroblasts were washed
with reduced serum Opti-MEM I medium (Invitrogen,
Carlsbad, CA, USA) and transfected with 20-MOE-modified
oligonucleotides (2.5–100 nM) with 4 ml/ml Lipofectamine
2000 (Invitrogen) at 378C for 5–7 h. The medium was then
removed and replaced with fresh culture medium, and the
fibroblasts were cultured for an additional 1–5 days.
RT–PCR studies
RNA was prepared with Trizol reagent (Gibco, Rockville,
MD, USA), and RT–PCR reactions were performed with
AmpliTaq (ABI, Foster City, CA, USA) and 50 ng of
cDNA. A portion of the prelamin A transcript (corresponding
to exon 8–12 sequences) was amplified with oligonucleotides
50-GATGATCCCTTGCTGACTTAC-30 and 50-GATTACAT
GATGCTG CAGTTCTG-30. The thermal cycling conditions
were as follows: 958C for 3 min, 958C for 15 s, 608C for
30 s and 728C for 15 s (for a total of 26 cycles). PCR products
were size-fractionated on 1.3% agarose gels, and DNA was
visualized by ethidium bromide staining and UV photography
or by SYTO 60 staining (Invitrogen) (1:16 000 dilution) and
imaging with an Odyssey infrared scanner (LI-COR Bio-
sciences, Lincoln, NE, USA).
Levels of progerin transcripts were quantified by SYBR
Green-based quantitative RT–PCR with previously described
primers and reaction conditions (4). Levels of other transcripts
were also measured by quantitative PCR with the oligonucleo-
tide primers listed in Supplementary Material, Table S2.
Western blot analysis
Fibroblasts were washed with phosphate-buffered saline, and
urea-soluble extracts were prepared as described (35).
Protein extracts were size-fractionated on 4–12% gradient
SDS–polyacrylamide Bis-Tris gels (Invitrogen), and the sep-
arated proteins were electrophoretically transferred to a sheet
of nitrocellulose. Western blots were performed with a 1:400
dilution of anti-lamin A/C goat IgG (sc-6215, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and a 1:1000 dilution
of goat anti-actin goat IgG (sc-1615, Santa Cruz Biotechnol-
ogy). Antibody binding was detected with a 1:6000 dilution
of horseradish peroxidase-labeled anti-goat IgG (sc-2020,
Santa Cruz Biotechnology) and the ECL Plus chemilumines-
cence system (GE Healthcare, Buckinghamshire, UK) or
with a 1:6000 dilution of IRDye 700 anti-goat IgG antibody
(Rockland Immunochemicals, Gilbertsville, PA, USA) and
scanning on the Odyssey infrared image scanner.
In some studies, lamins A, lamin C and progerin were iso-
lated by immune precipitation. For these experiments, cell
pellets collected from six-well plates were resuspended in
0.3 ml ice-cold lysis buffer (50 mM Tris, 0.15 M NaCl, 1 mM
EDTA, 1% NP-40, 2.5 mg/ml deoxycholate, 0.1% SDS,
1 mM PMSF) containing Complete Mini protease inhibitors
(Roche, Indianapolis, IN, USA) and incubated on ice for
10 min. After removing insoluble material by centrifugation,
cell extracts were pre-cleared by incubating with 25 ml of
Protein G–agarose (50% suspension in lysis buffer) (Roche)
at 48C for 30 min. Next, goat anti-lamin A/C antibody
(15 ml) (Santa Cruz Biotechnology) was added and incubated
overnight at 48C. Immune complexes were isolated with
Protein G–agarose (48C for 2 h), followed by centrifugation.
The bound proteins were released by boiling for 3 min in
SDS–PAGE loading buffer containing 2-ME.
Metabolic labeling studies
Fibroblasts were incubated for 36 h with an analog of farnesol,
AG (30 mM) (36) in the presence and absence of a protein FTI
ABT-100. Cell extracts were prepared and the proteins ana-
lyzed by western blotting with an AG-specific monoclonal
antibody (36). Binding of the antibody was detected with a
1:5000 dilution of IRDye 700 anti-mouse IgG antibody
(Rockland Immunochemicals) and infrared scanning. In some
studies, lamin proteins were isolated by immune precipitation
prior to analysis.
Microscopy and analysis of nuclear shape
Fibroblasts were grown on coverslips, fixed in 3% paraformal-
dehyde, permeabilized with 0.2% Triton X-100 and blocked
with PBS containing 10% fetal bovine serum and 0.2%
bovine serum albumin (23). Cells were incubated for 1 h
with antibodies against LAP2b (1:200, BD Transduction Lab-
oratories, San Jose, CA, USA) followed by a 1:600 Alexa
Fluor 488-conjugated anti-mouse antibody (A21202, Molecu-
lar Probes). DNA was visualized with DAPI. Images were
obtained on an Axiovert 200 MOT microscope (Carl Zeiss,
Thornwood, NY, USA) with a 63  1.25 oil immersion objec-
tive and processed with AxoVision 4.2 software (Zeiss).
Nuclear shape abnormalities were scored by two independent
observers blinded to genotype (8,11,23). Differences in the
numbers of misshapen nuclei were assessed with a x2-test.
2D-DIGE
Proteomic analysis of cells was performed by 2D-DIGE.
Fibroblasts in six-well plates were treated with ASO 324
(which promotes ‘HGPS splicing’) or ASO 333 (the control
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oligonucleotide), and after 2 days the cells were harvested.
The cell pellets were frozen in liquid nitrogen and stored at
2808C until analysis. The samples were analyzed by
Applied Biomics (Hayward, CA, USA). Equal amounts of
protein were labeled with cyanine dyes (e.g. Cy2, Cy3),
mixed together and separated by 2D-gel electrophoresis. The
gels were imaged on a Typhoon TRIO scanner (American Bio-
sciences) and individual protein spots were quantified with
DeCyder software (version 6.5) after normalization to an
internal standard generated by mixing equal portions of the
two test samples and labeling with a third dye (e.g. Cy5).
To identify protein spots of interest, preparative gels were
run, stained with Deep Purple and the stained proteins
imaged with DeCyder software. Protein spots were picked
with an Ettan Spot Picker (Amersham Biosciences), digested
with trypsin and analyzed by MALDI-TOF/TOF with an
ABI 4700 mass spectrometer. The NCBI database was
searched with MASCOT and candidates with either protein
C.I.% or Ion C.I.% score . 95 were considered significant.
All of the proteins identified had protein C.I.% scores . 97%.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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